BELLICUM PHARMACEUTICALS, INC·4

Dec 23, 4:30 PM ET

BELLICUM PHARMACEUTICALS, INC 4

4 · BELLICUM PHARMACEUTICALS, INC · Filed Dec 23, 2014

Insider Transaction Report

Form 4
Period: 2014-12-23
Transactions
  • Conversion

    Common Stock

    2014-12-23+298,434445,492 total(indirect: By McGuyer Investments Ltd.)
  • Conversion

    Common Stock

    2014-12-23+1,227,1321,672,624 total(indirect: By McGuyer Investments Ltd.)
  • Conversion

    Common Stock

    2014-12-23+301,8421,974,466 total(indirect: By McGuyer Investments Ltd.)
  • Conversion

    Common Stock

    2014-12-23+196,1972,170,663 total(indirect: By McGuyer Investments Ltd.)
  • Other

    Common Stock

    2014-12-23+44,7352,215,398 total(indirect: By McGuyer Investments Ltd.)
  • Conversion

    Series A Convertible Preferred Stock

    2014-12-23507,3390 total(indirect: By McGuyer Investments Ltd.)
    Common Stock (298,434 underlying)
  • Conversion

    Series B Convertible Preferred Stock

    2014-12-232,086,1250 total(indirect: By McGuyer Investments Ltd.)
    Common Stock (1,227,132 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2014-12-23513,1330 total(indirect: By McGuyer Investments Ltd.)
    Common Stock (301,842 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2014-12-23333,5360 total(indirect: By McGuyer Investments Ltd.)
    Common Stock (196,197 underlying)
Footnotes (6)
  • [F1]The Reporting Person has voting and investment power held by McGuyer Investments Ltd. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  • [F2]Reflects 1.7-for-1 reverse stock split which became effective on December 5, 2014.
  • [F3]The Series A Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
  • [F4]The Series B Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
  • [F5]The Series C Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.
  • [F6]On December 4, 2014, the Board of Directors of the Issuer declared a dividend payable to all holders of records of the Series B Convertible Participating Preferred Stock of the Issuer on December 16, 2014, payable in the form of cash or in shares of Common Stock of the Issuer, at the option of each holder. The dividends occurred in connection with the closing of the Issuer's public offering. The Reporting Person elected to receive the shares of Common Stock.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION